How to Get Vyleesi in Connecticut: Prescriptions, Telehealth, and Pharmacy Guide

What Is Bremelanotide (Vyleesi) and Who Qualifies in Connecticut

Bremelanotide is an FDA-approved melanocortin receptor agonist indicated for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval on June 21, 2019, based on the RECONNECT trial program. Qualifying patients in Connecticut are premenopausal women whose low sexual desire causes marked distress and is not explained by a co-existing medical condition, relationship problem, or medication side effect.

HSDD is diagnosed using validated instruments. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Desire (FSDS-DAO) are both referenced in the prescribing literature and clinical research [1]. Patients must report distress tied specifically to low desire, not to pain, arousal disorder, or orgasm dysfunction, for the HSDD label to apply.

The RECONNECT trial program enrolled 1,247 premenopausal women across two identical Phase 3 studies (RECONNECT A and RECONNECT B). At 24 weeks, statistically significant improvements were found on the FSDS-DAO desire item score and on the FSFI desire domain score compared with placebo (P<0.001 for both co-primary endpoints in the pooled analysis) [1]. Nausea occurred in 40% of participants, making it the most common adverse effect [2].

Bremelanotide acts on MC1R and MC4R receptors in the central nervous system rather than on sex hormones, which distinguishes it mechanistically from flibanserin (Addyi), the only other FDA-approved HSDD medication [3]. Connecticut providers who already manage flibanserin prescriptions often transition patients to bremelanotide when nightly dosing adherence is difficult, because Vyleesi is taken only as needed.

Connecticut Telehealth Rules for Vyleesi Prescriptions

Connecticut fully permits telehealth prescribing of Vyleesi. An audio-visual telehealth encounter satisfies the prescriber-patient relationship requirement under Connecticut General Statutes Section 19a-906, which governs telehealth practice in the state [4]. Audio-only encounters may not be sufficient for an initial HSDD evaluation because the clinical interview and questionnaire review benefit from real-time communication.

Connecticut adopted the Interstate Medical Licensure Compact (IMLC), so physicians licensed in compact member states can prescribe to Connecticut patients if they hold a valid compact license. Nurse practitioners in Connecticut operate under collaborative agreements in certain settings, though full practice authority legislation has expanded their independent prescribing rights. Physician assistants prescribe under supervision agreements with a collaborating physician.

Telehealth platforms specializing in women's sexual health have expanded into Connecticut since 2021. A typical telehealth pathway proceeds as follows. The patient completes an intake questionnaire covering sexual history, distress scores, cardiovascular history, and current medications. The provider reviews the intake, conducts a synchronous video visit (usually 20 to 30 minutes), and issues a prescription electronically to a pharmacy of the patient's choice. Some platforms send the prescription directly to a partnered mail-order pharmacy, cutting fulfillment time.

The FDA prescribing information for bremelanotide requires providers to check a patient's blood pressure before prescribing because the drug transiently increases blood pressure by an average of 2 mmHg systolic in the first 12 hours after injection [2]. Patients with uncontrolled hypertension or cardiovascular disease are excluded from treatment. Telehealth providers accomplish this check by requesting a recent blood pressure reading documented in a pharmacy, clinic, or home-monitoring log.

Patients should confirm that their telehealth provider holds a Connecticut license or a valid IMLC compact license before the appointment. The Connecticut Department of Public Health license verification portal allows patients to search any licensed clinician [4].

Labs and Medical Evaluation Required Before Starting Vyleesi in Connecticut

No mandatory laboratory panel is required by the FDA label before initiating bremelanotide. The evaluation is primarily clinical, focused on ruling out organic causes of low libido and identifying contraindications.

Providers typically order or review the following before prescribing:

• A recent blood pressure measurement (within 30 days) to rule out uncontrolled hypertension
• Thyroid-stimulating hormone (TSH) to exclude hypothyroidism as a reversible driver of low desire [5]
• Total and free testosterone, DHEA-S, and prolactin when the history suggests hormonal dysregulation [6]
• A complete medication review to identify libido-suppressing drugs such as SSRIs, antipsychotics, or hormonal contraceptives [7]

The Endocrine Society Clinical Practice Guideline on female sexual dysfunction notes that prolactin measurement is appropriate when HSDD is accompanied by galactorrhea or menstrual irregularity [6]. Thyroid function testing is similarly recommended when fatigue and weight changes accompany low desire [5].

Blood pressure measurement is the single non-negotiable check before each dose, not just at baseline. The Vyleesi prescribing information states: "Measure blood pressure within 2 hours after each injection and do not administer to patients with uncontrolled hypertension or known cardiovascular disease" [2]. Telehealth providers routinely instruct patients to own a validated home blood pressure cuff before the first dose.

Pregnancy testing is not mandatory in the label, but most Connecticut providers include it for patients with irregular cycles because bremelanotide has not been studied in pregnant women and the label recommends discontinuation if pregnancy occurs [2].

The HealthRX clinical team recommends a structured pre-prescription checklist for Connecticut telehealth visits:

1. FSFI and FSDS-DAO scores documented in the chart
2. Blood pressure within the past 30 days (below 140/90 mmHg)
3. TSH, free T4, prolactin if clinically indicated
4. Medication reconciliation with attention to libido-affecting drugs
5. Confirmation that patient is premenopausal and not currently pregnant
6. Documented patient distress tied specifically to low desire (not pain or arousal)

This checklist mirrors the evaluation framework described in the ISSWSH (International Society for the Study of Women's Sexual Health) Process of Care for HSDD [8].

Prior Authorization for Vyleesi Under Connecticut Medicaid and Commercial Plans

Connecticut Medicaid covers bremelanotide with prior authorization (PA) for qualifying premenopausal women with HSDD. The PA process requires documentation that meets criteria similar to those used by most commercial insurers operating in the state.

Standard PA documentation in Connecticut includes:

• A confirmed HSDD diagnosis supported by validated distress-scale scores
• Evidence that the patient is premenopausal
• Confirmation that no reversible organic cause of low desire has been left unaddressed
• In some plans, documentation that the patient has trialed or considered flibanserin first (step therapy)

Step therapy requirements vary by plan. Anthem Blue Cross Blue Shield of Connecticut, ConnectiCare, and Cigna all maintain individual PA criteria that may require a trial of non-pharmacological interventions (such as sex therapy or counseling) before approving a branded medication. Providers should request the plan's specific HSDD or "female sexual dysfunction" criteria letter before submitting.

The Vyleesi manufacturer, Palatin Technologies, offers a patient assistance program called the Vyleesi Cares program, which may reduce out-of-pocket costs for commercially insured patients who do not qualify for Medicaid [9]. Patients without insurance coverage who do not qualify for Palatin's program face a list price near $800 per carton (four auto-injectors). That cost makes prior authorization pursuit worthwhile for most Connecticut patients.

PA appeals in Connecticut are governed by state managed care regulations. Patients denied coverage have the right to an expedited internal appeal within 72 hours and an external review under Connecticut Insurance Department rules [10]. Providers who document FSDS-DAO scores and blood pressure data at the initial visit produce stronger PA submission packets.

Connecticut 503A Pharmacy Access for Bremelanotide

Licensed 503A compounding pharmacies in Connecticut may compound bremelanotide for individual patient prescriptions, provided they operate under state pharmacy board oversight and comply with USP Chapter 797 sterile compounding standards [11]. Compounded bremelanotide is not FDA-approved, meaning patients and providers choose this route only when the branded product is inaccessible due to cost, supply, or formulary gaps.

The FDA's list of bulk drug substances under consideration for compounding does not currently include bremelanotide as a Category 1 (approved for compounding) substance [12]. This regulatory status means 503A pharmacies compound bremelanotide under the general provisions of Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding for individual patients based on a valid prescription. Patients should ask their pharmacy for a copy of the certificate of analysis for each batch to confirm potency and sterility.

Connecticut's Department of Consumer Protection, Pharmacy Section, licenses and inspects compounding pharmacies in the state. Out-of-state 503A pharmacies that ship to Connecticut patients must hold non-resident pharmacy permits issued by the Connecticut Department of Consumer Protection [13]. Patients ordering from out-of-state compounders should verify that permit status before providing credit card information.

Compounded bremelanotide is typically supplied as a lyophilized powder for reconstitution or as a pre-mixed solution at 1.75 mg per dose, matching the branded product's dose strength. Storage requirements are the same: refrigerate at 36 to 46 degrees Fahrenheit; do not freeze [2].

The HealthRX clinical team advises patients to use FDA-approved Vyleesi when cost barriers can be addressed through insurance or patient assistance programs, reserving compounded bremelanotide for situations where the branded product is genuinely unavailable. This position aligns with FDA guidance on the appropriate use of compounded drugs [12].

How Long Does It Take to Get Vyleesi in Connecticut

Most Connecticut patients receive their first supply of bremelanotide within 3 to 7 business days of a successful telehealth or in-person visit, assuming no PA is required. The timeline extends when prior authorization is needed.

Typical timeline by scenario:

• Cash-pay or commercial insurance (no PA required): Telehealth visit to delivery in 3 to 5 business days via mail-order pharmacy.
• Commercial insurance with PA: Add 5 to 10 business days for PA processing. Expedited PA for urgent cases may reduce this to 72 hours.
• Connecticut Medicaid with PA: 7 to 14 business days in most cases, though the state requires insurers to process standard PA requests within 3 business days under Connecticut law [10].
• Compounded bremelanotide from a 503A pharmacy: Varies by pharmacy; most ship within 3 to 5 business days of receiving a valid prescription.

Specialty pharmacy networks that carry Vyleesi directly include CVS Specialty, Walgreens Specialty, and Optum Specialty Pharmacy, all of which serve Connecticut patients by mail. Retail pharmacy availability of Vyleesi is limited because the product requires refrigerated storage; calling ahead to confirm stock is advisable before routing a prescription to a local pharmacy.

Patients who need bremelanotide quickly can request an expedited PA if clinical urgency is documented. Connecticut law requires managed care organizations to respond to expedited PA requests within 72 hours [10].

Transferring an Existing Vyleesi Prescription to Connecticut

Transferring a Vyleesi prescription to Connecticut is straightforward if the original prescriber holds licensure that permits prescribing to Connecticut residents. Connecticut accepts electronically transmitted prescriptions from out-of-state licensed prescribers, provided the prescription meets Connecticut controlled-substance and non-controlled prescription requirements.

Bremelanotide is not a controlled substance, which simplifies transfer. A pharmacist in Connecticut can receive a transferred prescription for bremelanotide from an out-of-state pharmacy under standard transfer rules, as long as it has not already been partially dispensed.

If the original prescriber is not licensed in Connecticut, the patient needs a new evaluation from a Connecticut-licensed provider. Most telehealth platforms offer this efficiently. The new provider reviews prior records and, when appropriate, can issue a new prescription at the same dose without requiring the full diagnostic workup from scratch, provided the chart notes document the original HSDD diagnosis and treatment response [8].

Insurance coverage does not transfer automatically. If a patient moves to Connecticut and enrolls in a new plan, a new PA may be required even if the prior plan approved Vyleesi. Bring the original PA approval letter and any prior treatment records to the new insurer's PA submission.

Who Can Prescribe Vyleesi in Connecticut

Connecticut permits MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe bremelanotide, subject to their respective scope-of-practice rules.

MDs and DOs hold independent prescribing authority without supervision requirements. NPs in Connecticut have operated under collaborative practice agreements historically, though the state has progressively expanded NP independence. PAs prescribe under a supervisory agreement with a collaborating physician. OB/GYNs, family medicine physicians, and internal medicine physicians most commonly encounter and evaluate HSDD in clinical practice [6].

The ISSWSH Process of Care consensus document, endorsed by the American College of Obstetricians and Gynecologists (ACOG), supports the role of general practitioners in diagnosing and treating HSDD when appropriate screening tools are used [8]. Connecticut OB/GYN practices affiliated with Yale New Haven Health and Hartford HealthCare both maintain women's sexual health programs where bremelanotide is an available treatment option.

Prescribers who are new to HSDD management can access the ISSWSH clinical training resources and the ACOG Practice Bulletin on sexual dysfunction for guidance [14]. The FDA label for Vyleesi is also a practical prescribing reference [2].

Managing Vyleesi Side Effects: What Connecticut Patients Should Know

Nausea is the most reported side effect in clinical data. In RECONNECT, 40% of bremelanotide-treated patients reported nausea versus 1% on placebo [1]. Hyperpigmentation of the face, gums, and breasts occurred in 1% of patients with extended use [2]. Transient blood pressure elevation averaging 2 mmHg systolic and 1 mmHg diastolic occurred within 12 hours of injection [2].

Managing nausea reduces dropout. Taking bremelanotide on a light stomach and pre-treating with an over-the-counter antiemetic such as ondansetron (if prescribed) or dimenhydrinate may reduce nausea severity [15]. The label recommends that patients rest for up to 12 hours if nausea is significant after injection.

Patients with dark skin types face higher risk of persistent hyperpigmentation, and the prescribing information notes this as a reason to consider discontinuing treatment in patients who develop the finding [2]. Connecticut providers should document baseline skin appearance and counsel patients accordingly at the initiation visit.

Because bremelanotide can lower blood pressure in combination with certain cardiovascular drugs and raise it transiently post-injection, patients taking antihypertensives need careful monitoring. The drug is contraindicated in patients with known cardiovascular disease, a point emphasized in the FDA label [2].

Practical Steps: Getting Vyleesi in Connecticut Starting This Week

A clear action plan reduces the time between decision and first dose:

1. Schedule a telehealth visit with a Connecticut-licensed provider who manages women's sexual health. The visit can occur the same week for most platforms.
2. Complete the FSFI and FSDS-DAO questionnaires before the visit. Many platforms send these electronically in advance.
3. Measure blood pressure at home or at a pharmacy kiosk within 48 hours before the visit.
4. Gather any relevant prior records, including previous HSDD diagnoses, flibanserin trials, or hormone test results.
5. Confirm insurance benefits for Vyleesi before the visit to determine whether PA will be needed.
6. After the visit, ask the provider to route the prescription to a specialty pharmacy with Connecticut delivery service.
7. If PA is required, ask the provider's staff to submit within 24 hours of the visit to minimize delay.

Palatin Technologies' Vyleesi Cares support line (1-844-895-3347) assists patients with PA submissions and cost support for commercially insured patients who meet income criteria [9].

The RECONNECT pooled data showed that 25% of patients rated themselves "much improved" or "very much improved" on the Patient Global Impression of Change scale at week 24 on bremelanotide versus 17% on placebo (P<0.01) [1]. For women in Connecticut who have not responded to non-pharmacological approaches, a telehealth visit this week is a reasonable next step. Connecticut prescribers can initiate Vyleesi treatment at 1.75 mg per dose, administered subcutaneously in the abdomen, upper thigh, or upper arm, no more than once every 24 hours and no more than eight times per month [2].